Division of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, VIC, Australia; Department of Medical Oncology, Western Health, VIC, Australia; Department of Medical Oncology, Latrobe Regional Hospital, VIC, Australia.
Division of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, VIC, Australia.
Curr Probl Cancer. 2022 Apr;46(2):100793. doi: 10.1016/j.currproblcancer.2021.100793. Epub 2021 Sep 20.
For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This study aims to investigate the efficacy and safety of TAS-102 in a real-world population from Victoria, Australia. A retrospective analysis of prospectively collected data from the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry was undertaken. The characteristics and outcomes of patients receiving TAS-102 were assessed and compared to those enrolled in the registration study (RECOURSE). Across 13 sites, 107 patients were treated with TAS-102. The median age was 60 years (range: 31-83), compared to 63 for RECOURSE. Comparing registry TAS-102-treated and RECOURSE patients, 75% vs 100% were ECOG performance status 0-1, 74% vs 79% had initiated treatment more than 18 months from diagnosis of metastatic disease and 36% vs 49% were RAS wild-type. Median time on treatment was 10.4 weeks (range: 1.7-32). Median progression-free survival (PFS) was 3.3 months compared to 2 months in RECOURSE, while median overall survival was the same at 7.1 months. Two patients (2.3%) had febrile neutropenia and there were no treatment-related deaths, where TAS-102 dose at treatment initiation was at clinician discretion.TRACC registry patients treated with TAS-102 were younger than those from the RECOURSE trial, with similar overall survival observed. Less strict application of RECIST criteria and less frequent imaging may have contributed to an apparently longer PFS.
对于难治性转移性结直肠癌（mCRC）患者，使用三氟胸苷/替匹嘧啶（也称为 TAS-102）治疗可提高总生存期。本研究旨在调查 TAS-102 在澳大利亚维多利亚州真实世界人群中的疗效和安全性。对治疗复发性和晚期结直肠癌（TRACC）登记处前瞻性收集数据进行了回顾性分析。评估并比较了接受 TAS-102 治疗的患者的特征和结局与登记研究（RECOURSE）中入组的患者。在 13 个地点，有 107 名患者接受了 TAS-102 治疗。中位年龄为 60 岁（范围：31-83），而 RECOURSE 为 63 岁。与登记处 TAS-102 治疗组和 RECOURSE 组相比，75% vs 100%的患者 ECOG 体能状态为 0-1，74% vs 79%的患者从转移性疾病诊断开始治疗时间超过 18 个月，36% vs 49%的患者为 RAS 野生型。中位治疗时间为 10.4 周（范围：1.7-32）。中位无进展生存期（PFS）为 3.3 个月，而 RECOURSE 为 2 个月，中位总生存期相同，均为 7.1 个月。有 2 名患者（2.3%）发生发热性中性粒细胞减少症，无治疗相关死亡，TAS-102 起始剂量由临床医生决定。接受 TAS-102 治疗的 TRACC 登记处患者比来自 RECOURSE 试验的患者年轻，观察到总生存期相似。更宽松地应用 RECIST 标准和较少的频繁成像可能导致 PFS 明显延长。
